However, with Shi and colleagues showing that prostate cancer cells treated with aspirin significantly reduce MMP9 activity without any effect on MMP2 activity72, and an aspirin analogue ATL-1 capable of inactivating FAK in ECs73, the effect of aspirin on cancer cells is complex and yet to be fully elucidated. This evidence concerns the gene PTK2 and prostate carcinoma.